Europe meets the shortage of drugs, including the usual antibiotics that doctors prescribe patients, is stated in the new report of the European Audit Court.
Bosnia and Herzegovina also faces the shortage of medicines.
As they said from the BiH Medicine and Medical Auster, in 2025. Years from the drug manufacturers and the cost of placing the drug for foreign manufacturers, 151 drug shortages have been reported.
According to Prim. mr. Ph. Natasa Grubiše, director of the Agency, “of the specified number, 41 shortages referred to a lasting termination of the BiH market, while 110 applications refer to the temporary termination of the supply.”
– I would mention that such shortages, although recorded, do not represent a significant exportation compared to previous years, as the supply of various factors, including: supply chains, delays in production, increased demand, and other circumstances. In cases of permanent supply of supply, the most common reason is of the commercial nature, ie the lack of interest producers to continue the market placement in the BiH market – explains rougher.
Among the drugs for which the provisional traffic submitted this year are: Urutka, Urutka Forte, Imuran, Bonviva, as well as numerous medications for treatment from therapeutic areas such as diabetes, hypertension, oncological states …
When it comes to antibiotics, the coarse adds “Yes in 2025. No significant reports of the shortages of these medications were recorded.
– These are only a few medications for which lasting permanent or temporary suspension of traffic for commercial reasons, ie delays in the production of medicines. All listed drugs at the point of shortage of the shortage, a parallel on the BiH market, ie medicine with the same active substance in its composition, states Grubiš.
Due to the lack of transmission and permit holders, for a part of the shortages, as they say in the agency, they often learn from patients, health facilities and in other ways.
– In such cases, we contact manufacturers to verify the availability of medications and determining the reasons for the origin. I would remind all health workers and relevant subjects that in case of shortages always need to consider available substitute therapies, whether it is with the same active substance or drugs from the same pharmacotherapeutic group, of course, with a doctor and pharmacist – the Karbisha said Factor.
